GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trex Wind Down Inc (OTCPK:TMBRQ) » Definitions » ROE % Adjusted to Book Value

Trex Wind Down (Trex Wind Down) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Trex Wind Down ROE % Adjusted to Book Value?

Trex Wind Down's ROE % for the quarter that ended in Jun. 2023 was 0.00%. Trex Wind Down's PB Ratio for the quarter that ended in Jun. 2023 was N/A. Trex Wind Down's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was N/A.


Trex Wind Down ROE % Adjusted to Book Value Historical Data

The historical data trend for Trex Wind Down's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trex Wind Down ROE % Adjusted to Book Value Chart

Trex Wind Down Annual Data
Trend Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
-74.98 -56.01 -211.61

Trex Wind Down Quarterly Data
Apr19 Apr20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.96 -135.16 -227.54 -127.28 -

Competitive Comparison of Trex Wind Down's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Trex Wind Down's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trex Wind Down's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trex Wind Down's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Trex Wind Down's ROE % Adjusted to Book Value falls into.



Trex Wind Down ROE % Adjusted to Book Value Calculation

Trex Wind Down's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-209.49% / 0.99
=-211.61%

Trex Wind Down's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trex Wind Down ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Trex Wind Down's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Trex Wind Down (Trex Wind Down) Business Description

Traded in Other Exchanges
N/A
Address
3 Mountain View Road, Suite 100, Warren, NJ, USA, 07059
Timber Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its investigational therapies have mechanisms of action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The company is focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI), and other sclerotic skin diseases. The company's late-stage program is TMB-001., and TMB-003 is the earliest-stage program.
Executives
John Koconis director, officer: Chief Executive Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Alan Mendelsohn officer: Chief Medical Officer C/O TIMBER PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE A26, WOODCLIFF LAKE NJ 07677
Edward J Sitar director 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Lubor Gaal director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Kimberly Bragg officer: Controller C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Amir Tavakkol officer: Chief Scientific Officer C/O VIAMET PHARMACEUTICALS HOLDINGS LLC, 4505 EMPEROR BLVD., SUITE 300, DURHAM NC 27703
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Zachary Rome director, officer: Executive VP, COO and Sec. C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Joseph Lucchese officer: Executive VP & CFO C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Stocum director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Linda A Broenniman director 1895 PRESTON WHITE DR, STE 250, RESTON VA 20191
Gianluca Pirozzi director C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMITON AVENUE, SUITE 100, CAMPBELL CA 95008
Timber Pharmaceuticals Llc 10 percent owner 50 TICE BOULEVARD, SUITE A26, WOODCLIFF LAKE NJ 07677